Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P.
2008.
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.. Gastroenterology. 135(4):1130-41.
Scherl EJ, Kumar S, Warren RU.
2010.
Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.
Cohen-Mekelburg S, Schneider Y, Gold S, Ghosh G, Rosenblatt R, Hajifathalian K, Scherl E, Schnoll-Sussman F, Katz P, Steinlauf A.
2019.
Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care.. Dig Dis Sci. 64(8):2273-2279.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..
2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..
2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..
2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al..
2019.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.
Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al..
2017.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..
2021.
Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al..
2021.
Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.
Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H.
2015.
Treatment of metastatic cutaneous Crohn disease with certolizumab.. Dermatol Online J. 21(11)
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.
2015.
Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R.
2019.
The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.. Inflamm Bowel Dis. 25(6):1044-1053.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..
2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..
2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..
2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al..
2018.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.
Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al..
2017.
Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.
Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A.
2014.
Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.. Inflamm Bowel Dis. 20(6):1120-8.
Gordon BL, Galati J, Yang S, Katz PO, Scherl EJ.
2020.
Vitamin C Deficiency: An Under-Recognized Condition in Crohn's Disease.. ACG Case Rep J. 7(7):e00424.